Search Results - "Hettle R"

Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer" (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)'.

Authors: Hettle R McCrea C

Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Apr 17; Vol. 15, pp. 17588359231168519. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).

Publication Type: Journal Article; Comment

Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE

Cure Models: What is Meant by a Survival 'Plateau', and Do Experts Agree on What Constitutes One?

Authors: Jackson D Sweeting M Hettle R et al.

Source: PharmacoEconomics [Pharmacoeconomics] 2026 Jan; Vol. 44 (1), pp. 73-82. Date of Electronic Publication: 2025 Oct 14.

Publication Type: Journal Article

Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE

Is Genetic Testing of HER2-Negative Metastatic Breast Cancer Patients Implemented into Clinical Practice? A Retrospective Analysis.

Authors: Deutschmann, Christine Heinzl, Florian Leser, Carmen et al.

Source: Journal of Clinical Medicine. May2026, Vol. 15 Issue 9, p3433. 13p.

Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis.

Authors: Liu, Kun Zhou, Xiaofang Zhu, Youwen et al.

Source: Journal of Ovarian Research. 11/10/2025, Vol. 18 Issue 1, p1-10. 10p.

Real-World Treatment Patterns and Overall Survival (OS) of Patients with Metastatic Castration-Resistant Prostate Cancer in Italy.

Authors: Dovizio, Melania Castelletti, Daniela Luraghi, Paolo et al.

Source: Pragmatic & Observational Research. Nov2025, Vol. 16, p189-199. 11p.

Structured expert elicitation for long-term survival outcomes in health technology assessment: a systematic review.

Authors: Forsyth, Jessica E. Uttley, Lesley Wong, Ruth et al.

Source: BMC Medical Informatics & Decision Making. 10/21/2025, Vol. 25 Issue 1, p1-11. 11p.

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience.

Authors: Miao, Ruoyu Blue, Kirsten Sommerer, Katelyn et al.

Source: Cancers. Oct2024, Vol. 16 Issue 20, p3447. 11p.

Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis.

Authors: Zhu Y Zhou X Liu K et al.

Source: Journal of ovarian research [J Ovarian Res] 2026 Jan 28; Vol. 19 (1). Date of Electronic Publication: 2026 Jan 28.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE

Precision treatment patterns and prognostic analysis: A retrospective study of small-cell lung cancer.

Authors: Wang, Yiming Cheng, Xi Lin, Yaru et al.

Source: Journal of Cancer Research & Therapeutics. Sep2025, Vol. 21 Issue 4, p924-933. 10p.

Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis.

Authors: Rezaee, Mehdi Ravangard, Ramin Mojtabaeian, Seyyed Morteza et al.

Source: BMC Health Services Research. 10/29/2024, Vol. 24 Issue 1, p1-17. 17p.

Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis.

Authors: Fu, Shunlian Zou, Pingjin Fang, Zengyi et al.

Source: BMC Cancer. 1/31/2025, Vol. 25 Issue 1, p1-13. 13p.

Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial.

Authors: Lee J Kim M Jang M et al.

Source: Clinical drug investigation [Clin Drug Investig] 2026 May 08. Date of Electronic Publication: 2026 May 08.

Publication Type: Journal Article

Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE

Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects.

Authors: Lebedeva, Valeriia Ebbinghaus, Mira Hidalgo, José Villacorta et al.

Source: International Journal of Molecular Sciences. Oct2025, Vol. 26 Issue 19, p9714. 27p.

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

Authors: Zivadinov, Robert Keenan, Alexander J. Le, Hoa H. et al.

Source: BMC Neurology. 10/8/2024, Vol. 24 Issue 1, p1-12. 12p.

Response to discussant comments on "NMA, the first 20 years".

Authors: Ades, A. E. Welton, Nicky J. Dias, Sofia et al.

Source: Research Synthesis Methods. Sep2024, Vol. 15 Issue 5, p751-757. 7p.

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study.

Authors: Marzano, Luca Darwich, Adam S. Dan, Asaf et al.

Source: CTS: Clinical & Translational Science. Aug2024, Vol. 17 Issue 8, p1-15. 15p.

Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy.

Authors: Polistena, Barbara Provenzano, Anna Maria Rizzi, Caterina et al.

Source: Neurology & Therapy. Aug2025, Vol. 14 Issue 4, p1507-1520. 14p.

An investigation of the impact of using contrast- and arm-synthesis models for network meta-analysis.

Authors: Karahalios, Amalia White, Ian R. Turner, Simon L. et al.

Source: Research Synthesis Methods. Jul2025, Vol. 16 Issue 4, p631-649. 19p.

Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature.

Authors: Luvero, Daniela Angioli, Roberto Celoro, Federica et al.

Source: Pharmaceuticals (14248247). Jun2024, Vol. 17 Issue 6, p778. 12p.

Parametric analysis and model selection for economic evaluation of survival data.

Authors: Nemes, Szilárd¹, szilard.nemes@astrazeneca.com

Source: Model Assisted Statistics & Applications; 2024, Vol. 19 Issue 2, p123-131, 9p